DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Earl HM, Hiller L, Vallier AL. et al.
PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet 2019;
393 (10/191) 2599-2612
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.